Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1 – 45. (canceled)

46. (currently amended) A dosage form comprising:

a formulation comprising a therapeutic agent;

a first membrane in contact with said formulation, the first membrane consisting essentially of a hydrophobic substance and a hydrophilic substance exhibiting an aqueous solubility responsive to osmotic pressure and/or ionic strength of said formulation;

a second membrane positioned over an outside surface of said first membrane, wherein the second membrane is a semipermeable membrane that maintains its physical and chemical integrity as the dosage form dispenses the therapeutic agent ~~and the first and second membranes are formed such that the first membrane exhibits a permeability responsive to changes in osmotic pressure~~; and

at least one passageway formed across the membranes for dispensing the therapeutic agent from the dosage form.

47. (canceled)

48. (previously presented) The dosage form of claim 46, wherein said first and second membranes form an internal compartment containing the formulation.

49. (canceled)

50. (canceled)

51. (original) The dosage form of claim 46, wherein the integrity of the first membrane degrades during operation of the dosage form.

52. (canceled)

53. (previously presented) The dosage form of claim ~~52~~ 46, wherein the hydrophilicity of the hydrophobic substance changes in response to changes in osmotic pressure.

54. (original) The dosage form of claim 46, wherein the first membrane is formulated such that the permeability of the first membrane increases in response to a decrease in osmotic pressure.

55. (original) The dosage form of claim 46, wherein the formulation, the first membrane, and the second membrane are formulated and configured to deliver the therapeutic agent in an extended, non-declining release profile.

56. (original) The dosage form of claim 55, wherein the extended, non-declining release profile comprises a period of about 30 minutes to about 24 hours.

57. (original) The dosage form of claim 55, wherein the extended, non-declining release profile comprises a period of about 4 hours to about 24 hours.

58. (original) The dosage form of claim 46, wherein the formulation, the first membrane, and the second membrane, are formulated and configured to deliver the therapeutic agent in a zero-order release profile.

59. (original) The dosage form of claim 46, further comprising an expandable layer.

60. (currently amended) A method of delivering a therapeutic agent to a subject, the method comprising:

administering a dosage form to the subject, the dosage form comprising:

a formulation including the therapeutic agent,

a first membrane that is in contact with the formulation, the first membrane consisting essentially of a hydrophobic substance and a hydrophilic substance exhibiting an aqueous solubility response to osmotic pressure and/or ionic strength of said formulation,

and a second membrane positioned over an outside surface of said first membrane, wherein the second membrane is a semipermeable membrane that maintains its physical and chemical integrity as the dosage form dispenses the therapeutic agent ~~and the first and second membranes are formed such that the first membrane exhibits a permeability responsive to changes in osmotic pressure~~, and

at least one passageway formed across the membranes for dispensing the therapeutic agent from the dosage form.